Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Santiago Arroyo sold 26,954 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $15.91, for a total transaction of $428,838.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Santiago Arroyo also recently made the following trade(s):
- On Friday, October 18th, Santiago Arroyo sold 6,318 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $13.83, for a total transaction of $87,377.94.
Momenta Pharmaceuticals stock opened at $16.41 on Monday. The firm has a 50 day moving average of $14.12 and a 200 day moving average of $12.82. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -8.08 and a beta of 2.07. Momenta Pharmaceuticals, Inc. has a 12-month low of $9.51 and a 12-month high of $16.65.
Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings results on Thursday, October 31st. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.09). The firm had revenue of $6.40 million during the quarter, compared to analysts’ expectations of $5.24 million. Momenta Pharmaceuticals had a negative return on equity of 59.82% and a negative net margin of 361.66%. The company’s revenue was down 57.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.65) earnings per share. As a group, analysts predict that Momenta Pharmaceuticals, Inc. will post -2.59 EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Momenta Pharmaceuticals by 68.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,625 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 3,088 shares in the last quarter. Algert Global LLC purchased a new stake in Momenta Pharmaceuticals during the 2nd quarter valued at approximately $143,000. Bank of Montreal Can grew its holdings in Momenta Pharmaceuticals by 298.3% during the 2nd quarter. Bank of Montreal Can now owns 11,771 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 8,816 shares in the last quarter. CWM Advisors LLC grew its holdings in Momenta Pharmaceuticals by 17.2% during the 2nd quarter. CWM Advisors LLC now owns 13,780 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 2,020 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC purchased a new stake in Momenta Pharmaceuticals during the 2nd quarter valued at approximately $187,000. 96.30% of the stock is owned by institutional investors.
Several equities research analysts recently issued reports on MNTA shares. ValuEngine raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, November 1st. HC Wainwright started coverage on shares of Momenta Pharmaceuticals in a report on Wednesday, September 25th. They issued a “buy” rating and a $24.00 target price for the company. BidaskClub raised shares of Momenta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 31st. Wells Fargo & Co started coverage on shares of Momenta Pharmaceuticals in a report on Wednesday, November 6th. They issued an “outperform” rating for the company. Finally, Piper Jaffray Companies set a $35.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, September 17th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Momenta Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $22.53.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.